ASCO Gastrointestinal Cancers Symposium

Patient-Provider Conversations After a Bladder Cancer Diagnosis

February 5th 2024, 4:00pm

Video

There are a few conversations patients should have with their care teams after being diagnosed with bladder cancer — especially as new treatments become more available.

Slower Infusion of Antiemetic Drugs May Help With Nausea in GI Cancers

February 2nd 2024, 10:00pm

Video

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

An Oncologist Explains How She Uses ctDNA in Gastric Cancer

January 24th 2024, 10:00pm

Video

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.

Step Count Gives Insight to GI Cancer Outcomes in Older Patients

January 23rd 2024, 11:00pm

Video

Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.

Fruzaqla Delays Colorectal Cancer Progression, Prolongs Patient Survival

January 23rd 2024, 10:00pm

Article

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

Imfinzi, Avastin, TACE May ‘Set a New Standard of Care’ in Liver Cancer

January 23rd 2024, 4:00pm

Article

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.

Cancer in Bloodstream May Predict CRC Outcomes

January 23rd 2024, 2:00pm

Article

Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.

Poor Liver Function Can Cause Side Effects, Drug Discontinuation in HCC

January 22nd 2024, 11:00pm

Article

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.

Neoadjuvant Botensilimab/Balstilimab Produces Early Responses in CRC

January 22nd 2024, 8:00pm

Article

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.

Tecentriq-Tiragolumab-Chemo Combo Showed Improved Survival in ESCC

January 22nd 2024, 4:00pm

Article

In patients with esophageal squamous cell carcinoma, the combination of Tecentriq, tiragolumab and chemotherapy improved survival outcomes, research found.